A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02467387 |
Recruitment Status :
Completed
First Posted : June 10, 2015
Results First Posted : January 7, 2020
Last Update Posted : January 7, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non-Ischemic Heart Failure | Drug: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) Drug: Lactated Ringer's Solution | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 23 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Treatment |
Official Title: | A Phase IIa Randomized Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Non-ischemic Heart Failure |
Actual Study Start Date : | June 1, 2014 |
Actual Primary Completion Date : | May 11, 2017 |
Actual Study Completion Date : | May 11, 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: Experimental: Human (aMBMC)
Intervention: One time intravenous infusion of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more.
|
Drug: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)
One time infusion Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg.
Other Name: Mesenchymal Stem Cells, (MSC) Marrow Stromal Cells. |
Placebo Comparator: Placebo:Lactated Ringer's Solution (LRS)
Intervention: One time intravenous infusion of 1.5mL/kg Lactated Ringer's Solution (LRS) administered at a constant rate of approximately 2mL/min.
|
Drug: Lactated Ringer's Solution
One time infusion 1.5mL/kg
Other Name: (LRS) |
- Safety Will be Evaluated by Number of AE [ Time Frame: Total AEs and SAEs within 450 days post-infusion ]As identified in the SAP, the safety analysis was the primary objective and was evaluated by the number of AEs
- Change in LVEF From Baseline to Day 90 Post-initial Infusion. [ Time Frame: Baseline to Day 90 ]The secondary efficacy endpoint was the change in LVEF from baseline to Day 90 post-initial infusion. Participants with data available at each time point.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Males and females ≥18 years of age
- LVEF ≤35% on echocardiogram within 12 months of randomization to undergo MRI
-
Screening cardiac MRI at baseline with:
Ejection fraction ≤40% No significant hyper enhancement on MRI scan in the opinion of the central imaging lab reviewer
- Patients with non-ischemic heart failure etiology, as documented by absent or non-obstructive coronary artery disease on x-ray angiography or coronary computed tomography
- Patients with history of heart failure and treated for at least three months with GDMT
- NYHA class II-III symptoms
- Ability to understand and provide signed informed consent
- Reasonable expectation that patient will receive standard post-treatment care and attend all scheduled safety follow-up visits
Exclusion Criteria:
- Pregnant or nursing women or those of childbearing age and not using an effective method of contraception
- History of stroke within 3 months
- Cardiac surgery within 3 months prior to randomization or the likelihood of a requirement for such procedures during the study period
- Current ICD or CRT or implantation planned within 6 months of infusion
- Presence of clinically significant, uncorrected valvular heart disease, hypertrophic or restrictive cardiomyopathy, active myocarditis, or uncontrolled hypertension
- History of cardiac arrest or life-threatening arrhythmias within 3 months
- Treatment with parenteral inotropic agents within 1 month of randomization
- Anticipated cardiac transplantation within 1 year
- Illness other than heart failure with life expectancy less than 1 year
- Received an experimental drug or device within 30 days of randomization
- Left ventricular assist device or implantation planned in the next 6 months
- Patients with complex congenital heart disease
- Uncontrolled seizure disorder
- Presence of immune deficiency
-
Clinically significant hematologic, hepatic, or renal impairment as determined by screening clinical laboratory tests:
- Liver disease = ALT or AST > 3x normal, alkaline phosphatase or bilirubin >2x normal)
- Renal disease = estimated glomerular filtration rate as assessed by the MDRD formula <30 ml/min
- Hematologic = Unexplained leukocytosis >10 or hemoglobin < 9gm/dl
- Presence of any other clinically-significant medical condition, psychiatric condition, or laboratory abnormality, that in the judgment of the investigator or sponsor for which participation in the study would pose a safety risk to the subject
- Inability to comply with the conditions of the protocol
- Malignancy within the previous five years, except adequately treated basal cell carcinoma, provided that it is neither infiltrating nor sclerosing, and carcinoma in situ of the cervix
- Active myocarditis or early postpartum cardiomyopathy (within six months).
- Systemic corticosteroids, cytostatics, immunosuppressive drug therapy (cyclophosphamide, methotrexate, cyclosporine, azathioprine, etc.), and DNA depleting or cytotoxic drugs taken within four weeks prior to study treatment
- Porphyria
- Allergy to sodium citrate or any "caine" type of local anesthetic
- Any contraindication for gadolinium use for MRI
- Patient scheduled for hospice care
- Clinically relevant abnormal findings in the clinical history, physical examination, ECG, or laboratory tests at the screening assessment that would interfere with the objectives of the study or would preclude safe completion of the study. Abnormal findings could include: known HIV infection or other immunodeficiency state, chronic active viral infection (such as hepatitis B or C), acute systemic infections (defined as patients undergoing treatment with antibiotics), gastrointestinal tract bleeding, or any severe or acute concomitant illness or injury
- Any other medical, social, or geographical factor that would make it unlikely that the patient could comply with study procedures (e.g., alcohol abuse, lack of permanent residence, severe depression, disorientation, distant location, or noncompliance)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02467387
United States, District of Columbia | |
MedStar Washington Hospital Center | |
Washington, District of Columbia, United States, 20010 | |
United States, Georgia | |
Emory University Hospital | |
Atlanta, Georgia, United States, 30322 | |
United States, Illinois | |
Northwestern University Centers for Heart Failure Therapy | |
Chicago, Illinois, United States, 60611 | |
United States, New York | |
Stony Brook Heart Institute | |
Stony Brook, New York, United States, 11794 | |
United States, Pennsylvania | |
Hospital of the University of Pennsylvania, Heart Failure and Transplant Program | |
Philadelphia, Pennsylvania, United States, 19104 |
Study Director: | Kristrun Stardal, RN, BSN | Clinical Operations Manager |
Documents provided by CardioCell LLC:
Responsible Party: | CardioCell LLC |
ClinicalTrials.gov Identifier: | NCT02467387 |
Obsolete Identifiers: | NCT02123706 |
Other Study ID Numbers: |
STEM-104-M-CHF |
First Posted: | June 10, 2015 Key Record Dates |
Results First Posted: | January 7, 2020 |
Last Update Posted: | January 7, 2020 |
Last Verified: | December 2019 |
Non-ischemic Heart Failure Stem Cells |
Heart Failure Heart Diseases Cardiovascular Diseases |